References
Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Autologous bone marrow transplantation in the treatment of poor prognosis non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol 1984; 20: 217–2225.
Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Non-Hodgkin's malignant lymphoma. Therapeutic value of autologous bone marrow transplantation. Presse Med 1983; 12: 1917–1923.
Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.
Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010; 45: 1147–1153.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’slymphoma. J Clin Oncol 1999; 17: 3128–3135.
Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting forlymphoma:resultsfrom the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–1026.
Sharma A, Kayal S, Iqbal S, Malik PS, Raina V . Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus 2013; 2: 489.
Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43–48.
Jantunen E, Kuittinen T, Nousiainen T . BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151–1158.
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581–587.
Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant 2012; 10: 163–167.
Acknowledgements
KMA was supported by the UCL/UCLH Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kothari, J., Foley, M., Peggs, K. et al. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant 51, 1397–1399 (2016). https://doi.org/10.1038/bmt.2016.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.134
- Springer Nature Limited
This article is cited by
-
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM)
Bone Marrow Transplantation (2021)
-
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
Annals of Hematology (2021)
-
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma
Bone Marrow Transplantation (2019)